Avidity Biosciences

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO , March 27, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the following upcoming conferences: Cantor Fitzgerald Virtual Muscular Dystrophy Symposium on April 3 at 9:40 a.m. PT/ 12:40 p.m.

Avidity Biosciences to Participate in Upcoming Investor Conferences

SAN DIEGO , March 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on March 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 30,800 shares of its common stock and 15,400 restricted stock units ("RSUs") to three (3) new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan (the "2022 Inducement Plan"). The awards were granted as inducements material to the employees entering into employment with Avidity in accordance with Nasdaq Listing Rule 5635(c)(4).

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Top-notch biotech stock Avidity collapsed Monday despite unveiling "positive" midstage test results for its muscular dystrophy treatment.

Top 2% Biotech Avidity Collapses Despite 'Positive' Results In Treating Muscular Dystrophy

Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch

SAN DIEGO , Feb. 29, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced its support for Rare Disease Day®, highlighting the importance of bringing awareness to the devastating impact rare diseases have on patients, families and caregivers worldwide. "Today, on Rare Disease Day, we are proud to join the global community in raising awareness for people living with rare diseases," said Sarah Boyce, president and chief executive officer at Avidity.

Avidity Biosciences Honors Rare Disease Day®

Funding from new and existing investors, including Adage Capital Partners LP, Boxer Capital, Casdin Capital, LLC, Farallon, Janus Henderson Investors, RA Capital Management, RTW Investments, Wellington Management, as well as multiple large investment management firms Pro forma cash, cash equivalents and investments expected to provide runway into late 2026 Avidity to host Volume 8 of investor and analyst event series via webcast March 4, 2024, at 8:00 a.m. ET to present  AOC 1001 data from MARINA-OLE™ SAN DIEGO , Feb. 29, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it has agreed to sell 15,224,773 shares of its common stock at a price of $16.50 per share and pre-funded warrants to purchase 9,030,851 shares of its common stock at a price per pre-funded warrant of $16.4990 to a select group of institutional and accredited healthcare specialist investors in an oversubscribed private placement.

Avidity Biosciences Announces Oversubscribed $400 Million Private Placement

Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.88 per share a year ago.

Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Misses Revenue Estimates

Avidity is on-track to initiate global Phase 3 HARBOR™ trial of AOC 1001 for DM1 in mid-2024 Company to share first-look at long-term efficacy and safety data from MARINA-OLE™ trial in people living with DM1 at MDA Clinical & Scientific Conference and via webcast on March 4, 2024  Avidity to report data from clinical programs for people living with FSHD and DMD44 later this year SAN DIEGO , Feb. 28, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the fourth quarter and year ended December 31, 2023, and highlighted recent corporate progress. "With proven delivery of RNA to muscle and robust efficacy and long-term safety data from our ongoing clinical development programs, we are revolutionizing the delivery of RNA with our AOC technology," said Sarah Boyce, president and chief executive officer at Avidity.

Avidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Highlights

AbCellera Biologics

Vir Biotechnology

Investors know that the world of biotech stocks is home to a great percentage of opportunities that can triple and quadruple their capital. It's also fairly easy to identify such stocks using screener tools that can tease out such opportunities.

3 Highly Rated Biotech Stocks to Buy for 300% Gains

Avidity Biosciences, Inc. (RNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Strength Seen in Avidity Biosciences, Inc. (RNA): Can Its 15.0% Jump Turn into More Strength?

Avidity plans to initiate global Phase 3 HARBOR ™ trial of AOC 1001 for DM1 mid-2024 Company to report data from all three ongoing clinical programs in 2024  -- AOC 1001 data for DM1 in Q1, AOC 1020 data for FSHD in Q2, and AOC 1044 data for DMD44 in 2H -- Avidity to advance wholly-owned and partnered cardiology programs toward clinical development Avidity appoints Eric B. Mosbrooker as Chief Strategy Officer SAN DIEGO , Jan. 5, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced its 2024 corporate priorities and catalysts for the next stage of growth.

Avidity Biosciences Announces 2024 Corporate Priorities and Catalysts for Next Stage of Growth

Avidity (RNA) gains on the expansion of its existing partnership with BMY to discover multiple cardiovascular targets.

Avidity (RNA) Expands Collaboration With BMY, Shares Rise

Avidity Biosciences (NASDAQ: RNA ) stock is soaring in early trading after the company disclosed that it had expanded its partnership with a huge drugmaker, Bristol Myers Squibb (NYSE: BMY ). More About the RNA-BMY Deal Avidity and Bristol-Myers will increase the number of Antibody Oligonucleotide Conjugates (AOCs) on which they will collaborate in an effort to develop new cardiovascular treatments.

Why Is Avidity Biosciences (RNA) Stock Up 15% Today?

Bristol-Myers

Bristol Myers has agreed to pay Avidity $60 million in cash and will also purchase about $40 million of Avidity common stock at $7.88 a share.

Avidity Stock Soars on Collaboration Deal With Bristol Myers

Avidity Biosciences soared 35% in pre-market trading after announcing a global licensing and research collaboration with Bristol-Myers Squibb Co (NYSE:BMY).  The pact is focused on the discovery, development and commercialization of multiple cardiovascular targets with potential cumulative payments of up to $2.3 billion.

Avidity Biosciences leaps on Bristol-Myers research tie-up

Avidity Biosciences Inc. RNA said Tuesday it's expanding its cardiovascular collaboration with Bristol Myers Squibb Co. BMY in a deal that will see Avidity receive $100 million upfront with the potential to earn up to $2.2 billion in milestone payments. The news sent Avidity's stock up 21% in premarket trade.

Avidity's stock soars on news of expanded collaboration with Bristol Myers that includes potential to receive up to $2.2 billion in milestone payments

SAN DIEGO , Nov. 21, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating at the following upcoming conference: 6th Annual Evercore ISI HealthCONx Conference on November 28 at 9:30 a.m. PT/12:30 p.m.

Avidity Biosciences to Participate in Upcoming Investor Conference

Avidity reported new positive AOC 1001 data at World Muscle Society (WMS) Congress in October demonstrating consistent improvement in multiple additional functional endpoints and favorable long-term safety and tolerability in people living with myotonic dystrophy type 1 (DM1) AOC 1044 receives Orphan Designation for the treatment of DMD in US and EU Avidity remains on track to report data readouts from three clinical development programs – DM1, DMD and FSHD – over the next nine months SAN DIEGO , Nov. 8, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results and recent highlights for the third quarter ended September 30, 2023. Avidity ended the third quarter of 2023 with cash, cash equivalents and marketable securities totaling $542.6 million.

Avidity Biosciences Reports Third Quarter 2023 Financial Results and Recent Highlights

SAN DIEGO , Sept. 26, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the company will be presenting one oral and six poster presentations at the 28th Annual Congress of the World Muscle Society (WMS), being held October 3-7, 2023, in Charleston, South Carolina.

Avidity Biosciences Announces Upcoming Presentations at 28th Annual Congress of the World Muscle Society

Avidity supports World Duchenne Awareness Day, International Myotonic Dystrophy Awareness Day, FSHD Society Walk & Roll to Cure FSHD and Global Genes Week in RARE Avidity joins with MDF community leaders, patients, caregivers, and legislators in educational briefing to highlight the latest scientific advancements in myotonic dystrophy research and development Company advancing clinical development programs for three types of muscular dystrophy – DM1, DMD and FSHD – with planned data readouts over the next 12 months SAN DIEGO , Sept. 7, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it is joining with patient communities to raise awareness during National Muscular Dystrophy Awareness Month, an annual observance that takes place every September to support families across the U.S. who are impacted by neuromuscular diseases.

Avidity Biosciences Joins with Patient Communities to Raise Awareness During National Muscular Dystrophy Awareness Month as it Advances Three Muscular Dystrophy Clinical Programs

SAN DIEGO , Aug. 31, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the company will be presenting two poster presentations at the 2023 Myotonic Dystrophy Foundation Annual Conference, being held September 7-9, 2023, in Washington, D.C. POSTER PRESENTATIONS September 9, 2023: 12:30 p.m.

Avidity Biosciences Announces Upcoming Presentations at 2023 Myotonic Dystrophy Foundation Annual Conference

Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.92 per share a year ago.

Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Tops Revenue Estimates

Advancing three clinical development programs – DM1, DMD, FSHD - with data anticipated from each program over the next 12 months SAN DIEGO , Aug. 8, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results and recent highlights for the second quarter ended June 30, 2023. Avidity ended the second quarter of 2023 with cash, cash equivalents and marketable securities totaling $577 million.

Avidity Biosciences Reports Second Quarter 2023 Financial Results and Recent Highlights

Avidity Biosciences, Inc. stock is down significantly since my last article. The company, despite some early setback, is doing promising science. They have enough cash to execute their lead program.

Avidity Biosciences: Large Devaluation Of Stock Presents Opportunity

Avidity is currently enrolling participants in the Phase 1/2 FORTITUDE™ study of AOC 1020 for the treatment of FSHD Company anticipates data from a preliminary assessment in half of the participants in the FORTITUDE study in 1H 2024 SAN DIEGO , June 20, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), joins with the global community of patients, caregivers, and healthcare providers in support of World Facioscapulohumeral Muscular Dystrophy (FSHD) Day. FSHD is a serious, rare, hereditary muscle-weakening condition marked by life-long, progressive loss of muscle function that causes significant pain, fatigue, and disability.

Avidity Biosciences Joins with Patients, Caregivers and Healthcare Providers Globally to Support World Facioscapulohumeral Muscular Dystrophy (FSHD) Day

News for Avidity Biosciences Stock (RNA)